The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
My Accustem entitlement (over 19000 shares) is with Willis Owen, who don't allow overseas shares but can't tell me what will happen with them. They have, however, said I can transfer them to another provider.
I already had a shiny new empty ISA with HL, but they previously advised me I couldn't transfer in Accustem shares as they are "unable to accept transfer of a delisted stock". Given comments here, I have mailed them to make sure this is still the case.
I've emailed A J Bell today asking them if it's possible to transfer-in.
Lastly, given they've not been able to tell me what WILL happen, I've emailed Willis Owen to see if I get a period of grace to give me an opportunity to move them once the shares are listed before they dispose of them some other way outside my control.
I'll update once I get an answer. However I'm not kidding myself that these are gong to have much real value!!
Give it a rest please Oakleaf, you are disrupting every discussion with your apparent obsession with derampers. We can all make our own judgements and don't need yours continually repeated ad nauseum.
Probably best to ask your provider as there seem to be differences between them
I mentioned yonks ago that we wouldn't be IPOd. Initial Public Offering is when shares in a new company are put into the market, which then determines the value (by a number of means).
In our case all the shares already had owners, and a value, albeit from AIM.
Apart from some shared staff, TILS and Accustem are separate entities. What is this combined loss of which you speak?
Any grounds for that Jack, or just a wish?
Hello Jaykays
Who is Hanna and how come you have a hotline to her?
Thanks
... and I believe RNS (Regulatory news Service) is specific to the UK exchanges so as already said you need to find the NASDAQ equivalent, if one exists.
Accustem isn;t quoted on the LSE, it is listed on it. It will eventually be quoted and traded on the NASDAQ using the ADR mechanism.
That's how I understand it.
I can't see why Polygon, a financial company, would want to own a pharma. Not for themselves anyway.
I believe they just see a huge profit to be made in a short time, if all goes well. If they get and adequate size of holding that it becomes really significant I expect they will offer it, somehow, to someone more appropriate (Big Pharma). But I think they are hoping for a mahoosive payday just like the rest of us.
So presumably Deal3r the MM is dependent either on his existing stock of that share, or on scooping up from the open market...
What would happen if they simply could not get enough shares to fulfill the order? Or is that unlikely?
If the price is being "held" at , say, £1.60, what price is the deal likely to have been struck at? Something much higher, maybe £1.80? Otherwise the MM could be exposed to a high risk of a large loss surely, if even by raising the SP he couldn't readily persuade enough people to sell.